Does Butalbital Aspirin Caffeine And Codeine Phosphate Interact with Erythromycin?
CDI records a major classification for Butalbital Aspirin Caffeine And Codeine Phosphate and Erythromycin. The stored summary is: CYP3A4 inhibitor may increase codeine plasma concentrations and morphine levels, potentially causing fatal respiratory depression, particularly when added after stable dosing. The mechanism involves inhibition of cyp3a4 leads to increased codeine metabolism by cyp2d6, resulting in greater morphine levels. Patients taking both medications should consult their healthcare provider before starting, stopping, or changing the dosage of either drug. This record was extracted from drug labeling through openFDA. NIH/NLM RxNorm is used for drug identities. The summary and severity classification are CDI's processed information, not a verbatim source quotation. Product, route, and patient circumstances matter.
- Severity
- Major
- Butalbital Aspirin Caffeine And Codeine Phosphate Class
- Nonsteroidal Anti-inflammatory Drug
- Erythromycin Class
- Macrolide
- Management
- Close medical supervision required
- Data Source
- U.S. FDA via OpenFDA
Recorded Mechanism
Inhibition of CYP3A4 leads to increased codeine metabolism by CYP2D6, resulting in greater morphine levels
What To Tell Your Doctor or Pharmacist
If you are taking Butalbital Aspirin Caffeine And Codeine Phosphate and your doctor is considering prescribing Erythromycin (or vice versa), make sure to:
- Inform your doctor and pharmacist of all current medications, including over-the-counter drugs and supplements
- Ask whether the benefits of combining these medications outweigh the risks for your specific situation
- Ask what symptoms to watch for that would indicate the interaction is causing problems
- Ask how frequently you should be monitored while these are co-prescribed
- Ask whether any dosage adjustments are needed
- Never stop or change either medication without first consulting your healthcare provider